The FDA has approved the country’s first licensed meningitis B vaccine. Although there are approved vaccines for meningitis strains A, C, W and Y, there was no approved vaccine for the B strain until now. The vaccine, named Trumenba and developed by Pfizer, is intended for use in 10 to 25 year olds. Results from 3 randomized studies showed 82% of those vaccinated had antibodies in their blood that killed four different meningitidis serogroup B strains. Recent outbreaks on college campuses have drawn concern about the potentially deadly bacterial disease.
We would like to thank all of the patients who volunteered for our research studies involving the meningitis B vaccine. Up to 19% of meningitis survivors are left with disabilities such as brain damage and limb amputations, and 10 to 15% of patients who contract meningitis will die. Thanks to our research patients there may be disabilities avoided and lives saved because of this vaccine.
Read more about the vaccine approval and meningitis B here and here
